AbbVie (ABBV) Intangibles (2012 - 2026)
AbbVie (ABBV) reported Intangibles of $50.9 billion for Q1 2026, down 13.02% year-over-year from $58.5 billion in Q1 2025, and down 3.36% on a QoQ basis from $52.6 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Intangibles data on file, last reported at $50.9 billion in Q1 2026.
- Quarterly Intangibles fell 13.02% year-over-year to $50.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.9 billion (down 13.02% YoY) and the FY2025 annual result came in at $52.6 billion, down 12.36% from the prior year.
- Intangibles fell to $50.9 billion in Q1 2026 per ABBV's latest filing, from $52.6 billion in the prior quarter.
- Across five years, Intangibles topped out at $74.0 billion in Q1 2022 and bottomed at $711.0 million in Q3 2025.
- The 5-year median for Intangibles is $60.2 billion (2024), against an average of $58.4 billion.
- The widest annual swing landed in 2024, when Intangibles advanced 13.72%; it then slumped 98.93% in 2025.
- Tracing ABBV's Intangibles over 5 years: stood at $67.4 billion in 2022, then decreased by 17.54% to $55.6 billion in 2023, then advanced by 8.02% to $60.1 billion in 2024, then retreated by 12.36% to $52.6 billion in 2025, then dropped by 3.36% to $50.9 billion in 2026.
- Per Business Quant, the three latest ABBV Intangibles figures stand at $50.9 billion (Q1 2026), $52.6 billion (Q4 2025), and $711.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.37 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 49.06 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 50.87 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 18.24 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 22.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.87 Bn |
| Dec 31, 2025 | 52.64 Bn |
| Sep 30, 2025 | 711.00 Mn |
| Jun 30, 2025 | 57.03 Bn |
| Mar 31, 2025 | 58.49 Bn |
| Dec 31, 2024 | 60.07 Bn |
| Sep 30, 2024 | 66.65 Bn |
| Jun 30, 2024 | 60.24 Bn |
| Mar 31, 2024 | 62.23 Bn |
| Dec 31, 2023 | 55.61 Bn |
| Sep 30, 2023 | 58.60 Bn |
| Jun 30, 2023 | 62.86 Bn |
| Mar 31, 2023 | 64.85 Bn |
| Dec 31, 2022 | 67.44 Bn |
| Sep 30, 2022 | 68.73 Bn |
| Jun 30, 2022 | 71.82 Bn |
| Mar 31, 2022 | 73.99 Bn |
| Dec 31, 2021 | 75.95 Bn |
| Sep 30, 2021 | 77.46 Bn |
| Jun 30, 2021 | 79.34 Bn |
| Mar 31, 2021 | 81.29 Bn |
| Dec 31, 2020 | 82.88 Bn |
| Sep 30, 2020 | 74.64 Bn |
| Jun 30, 2020 | 76.46 Bn |
| Mar 31, 2020 | 18.20 Bn |
| Dec 31, 2019 | 18.65 Bn |
| Sep 30, 2019 | 19.04 Bn |
| Jun 30, 2019 | 20.46 Bn |
| Mar 31, 2019 | 20.85 Bn |
| Dec 31, 2018 | 21.23 Bn |
| Sep 30, 2018 | 6.10 Bn |
| Jun 30, 2018 | 26.90 Bn |
| Mar 31, 2018 | 27.23 Bn |
| Dec 31, 2017 | 27.56 Bn |
| Sep 30, 2017 | 28.17 Bn |
| Jun 30, 2017 | 28.37 Bn |
| Mar 31, 2017 | 28.63 Bn |
| Dec 31, 2016 | 28.90 Bn |
| Sep 30, 2016 | 29.11 Bn |
| Jun 30, 2016 | 19.27 Bn |
| Mar 31, 2016 | 19.51 Bn |
| Dec 31, 2015 | 19.71 Bn |
| Sep 30, 2015 | 19.82 Bn |
| Jun 30, 2015 | 12.36 Bn |
| Mar 31, 2015 | 6.11 Bn |
| Dec 31, 2014 | 80.00 Mn |
| Sep 30, 2014 | 6.13 Bn |
| Jun 30, 2014 | 6.20 Bn |
| Mar 31, 2014 | 1.80 Bn |
| Dec 31, 2013 | 1.44 Bn |
| Sep 30, 2013 | 6.18 Bn |
| Jun 30, 2013 | 1.66 Bn |
| Mar 31, 2013 | 6.06 Bn |
| Dec 31, 2012 | 1.90 Bn |